Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine 10ruxolitinib 9fludarabine phosphate 9Whole-Body Irradiation 9Specimen Handling 9Cyclophosphamide 8Azacitidine 8Mycophenolic Acid 7Cytarabine 7Busulfan 7Biopsy 7Tacrolimus 6venetoclax 5Stem Cell Transplantation 5Sirolimus 5Peripheral Blood Stem Cell Transplantation 5Injections 5Granulocyte Colony-Stimulating Factor 5Melphalan 4Cyclosporine 4CPX-351 4luspatercept 3ivosidenib 3decitabine and cedazuridine drug combination 3Thiotepa 3Methotrexate 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × iadademstat × 90 days × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡